Regnase-1 overexpression as a therapeutic approach of Marfan syndrome

Marie Noormalal,Nesrin Schmiedel,Tarik Bozoglu,Andrea Matzen,Susanne Hille,Dima Ibrahim Basha,Prithviraj Manohar Vijaya Shetty,Anja Wolf,Marcin Zaradzki,Rawa Arif,Thomas Pühler,Georg Lutter,Andreas H Wagner,Christian Kupatt,Derk Frank,Norbert Frey,Anca Remes,Oliver J Müller
DOI: https://doi.org/10.1016/j.omtm.2023.101163
2023-12-01
Abstract:Rupture or dissection of thoracic aortic aneurysms is still the leading cause of death for patients diagnosed with Marfan syndrome. Inflammation and matrix digestion regulated by matrix metalloproteases (MMPs) play a major role in the pathological remodeling of the aortic media. Regnase-1 is an endoribonuclease shown to cleave the mRNA of proinflammatory cytokines, such as interleukin-6. Considering the major anti-inflammatory effects of regnase-1, here, we aimed to determine whether adeno-associated virus (AAV)-mediated vascular overexpression of the protein could provide protection from the development and progression of aortic aneurysms in Marfan syndrome. The overexpression of regnase-1 resulted in a marked decrease in inflammatory parameters and elastin degradation in aortic smooth muscle cells in vitro. Intravenous injection of a vascular-targeted AAV vector resulted in the efficient transduction of the aortic wall and overexpression of regnase-1 in a murine model of Marfan syndrome, associated with lower circulating levels of proinflammatory cytokines and decreased MMP expression and activity. Regnase-1 overexpression strongly improved elastin architecture in the media and reduced aortic diameter at distinct locations. Therefore, AAV-mediated regnase-1 overexpression may represent a novel gene therapy approach for inhibiting aortic aneurysms in Marfan syndrome.
What problem does this paper attempt to address?